Despite some studies supporting context-specific roles for P38, for example in tamoxifen and HER2-targeted therapy resistance, there is mounting evidence that in primary breast cancer P38 has a tumour suppressive effect [5, 13–15]. The gene discussed is ERBB2; the disease is breast carcinoma.